Automated synthesis of [Ga]Ga-FAPI-46 without pre-purification of the generator eluate on three common synthesis modules and two generator types.

Background: The recent development of quinoline-based radiotracers, which act as fibroblast activation protein inhibitors (FAPIs), has shown promising preclinical and clinical advantages. [Ga]Ga-FAPI-46 is a new radiotracer for in vivo detection of the fibroblast activation protein by positron emission tomography (PET). Recently, the automated synthesis of [Ga]Ga-FAPI-46 was reported based on pre-concentration and purification of the generator eluate by using a cation exchange-cartridge.

A simple, reliable and accurate approach for assessing [I]-capsule activity leading to significant reduction of radiation exposure of medical staff during radioiodine therapy.

Purpose: According to German law, the [I]-capsule activity has to be checked in the context of radioiodine therapy (RIT) immediately before application. The measurement leads to significant radiation exposure of the medical personnel, especially of their hands. We aimed to establish a method for estimating [I]-capsule activity by measuring the dose rate (DR) at contact of the delivered lead closed container carrying the [I]-capsules and to evaluate radiation exposure in comparison to conventional [I]-capsule measurement using a dose calibrator.

Biodistribution and pharmacokinetics of the (99m)Tc labeled human elastase inhibitor, elafin, in rats.

Elafin is a potent reversible inhibitor of the pro-inflammatory proteases leukocyte elastase and protease 3. It is currently in clinical development for the use in postoperative inflammatory diseases. We investigated the pharmacokinetics of (99m)Tc-labeled elafin ((99m)Tc-Elafin) in blood and individual organs in rat after bolus intravenous injection using the single photon emission tomography (SPECT).